Sellas Life Sciences Group Inc Stock Price, News & Analysis

SELLAS Life Sciences Group (NASDAQ: SLS) has completed enrollment in a Phase 1/2 clinical trial for its lead asset, galinpepimut-S (GPS), in combination with Merck’s KEYTRUDA^® for advanced ovarian cancer. The trial aims to assess safety and efficacy in 17 patients, with interim data expected by mid-2022 and final results by the end of 2022. This milestone reflects SELLAS's commitment to improving treatment options for difficult-to-treat patients, despite challenges posed by COVID-19.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has had its IND application accepted by China’s NMPA to initiate a Phase I trial of 3D189 (GPS) for hematological malignancies, expected to start in mid-2022. This milestone will trigger a payment to SELLAS, with additional payments linked to further trials. GPS has shown encouraging results in prior studies and aims to improve outcomes for cancer patients globally. Collaboration with 3D Medicines may also extend to ongoing Phase III trials in AML, enhancing their combined treatment options.

SELLAS Life Sciences Group (NASDAQ: SLS) has announced the promotion of John T. Burns to Senior Vice President, Finance, and Chief Accounting Officer. Burns, who joined SELLAS in 2013, has played a vital role in the company’s financial strategy and execution. His promotion reflects his contributions to the company’s growth, particularly in advancing its clinical programs for cancer immunotherapies. SELLAS is developing innovative treatments, including galinpepimut-S and nelipepimut-S, targeting various cancer types.

SELLAS Life Sciences Group (NASDAQ: SLS) announced the final approval on November 19, 2021, by the United States District Court for the District of New Jersey regarding the settlement of claims related to its predecessor, Galena Biopharma, Inc.. This settlement resolves derivative actions Keller v. Ashton and Johnson v. Schwartz and mandates the adoption of new policies for future commercialization of clinical candidates. The company's insurer will cover attorney's fees up to $270,000. SELLAS focuses on developing cancer immunotherapies, with its lead product candidate, galinpepimut-S (GPS).

SELLAS Life Sciences Group (NASDAQ: SLS) reported Q3 2021 financial results, including a net loss of $7.1 million and no licensing revenue for the quarter. R&D expenses rose to $4.5 million, significantly up from $2.4 million in Q3 2020, driven by clinical trial activities for the Phase 3 REGAL study of galinpepimut-S (GPS) in AML. The company is also planning a Phase 2/3 study for GPS in post-BMT AML patients. As of September 30, 2021, cash equivalents stood at approximately $26.3 million, indicating ongoing financial support for its clinical initiatives.

SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical company focused on cancer immunotherapies, announced that CEO Angelos Stergiou will participate in two key conferences. The first is the Laguna Biotech CEO Forum from October 10-12, 2021, in Laguna Beach, CA. The second is the A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference on October 13, 2021, which will be held virtually. SELLAS aims to advance its immunotherapeutic candidates, galinpepimut-S and nelipepimut-S, targeting various cancer indications.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced preliminary court approval for a settlement related to derivative claims against former executives of its predecessor, Galena Biopharma. The settlement includes a stipulation that mandates the company to implement specific policies concerning future commercialization of its clinical candidates. Furthermore, the company's insurer will cover up to $270,000 in legal fees. A final settlement approval hearing is scheduled for November 19, 2021.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that CEO Angelos Stergiou will present at the 2021 Cantor Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. The company specializes in developing innovative cancer immunotherapies, notably its lead candidate galinpepimut-S (GPS), which targets the WT1 protein in various tumors, and nelipepimut-S (NPS), aimed at early-stage breast cancer patients. For further details about the conference or to arrange meetings, interested parties can contact Cantor representatives or KCSA Strategic Communications.

SELLAS Life Sciences Group (SLS) reported significant clinical updates on Galinpepimut-S (GPS), showcasing its potential in treating malignant pleural mesothelioma and WT1+ advanced ovarian cancer. The company highlighted results from a study showing an overall survival (OS) of 48.5 months for AML patients treated with GPS. Financially, SLS recorded licensing revenue of $1.9 million for Q2 2021, with a cash position of $29.9 million as of June 30, 2021. A virtual investor symposium is scheduled for August 17, 2021, to discuss further insights on GPS and its promising clinical data.